Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1

Esther Tijchon, Liesbeth van Emst, Laurensia Yuniati, Dorette van Ingen Schenau, Mylène Gerritsen, Laurens T van der Meer, Owen Williams, Peter M Hoogerbrugge, Blanca Scheijen, Frank N van Leeuwen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

5 Citaten (Scopus)


Translocation t(12;21) (p13;q22), giving rise to the ETV6-RUNX1 fusion gene, is the most common genetic abnormality in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This translocation usually arises in utero, but its expression is insufficient to induce leukemia and requires other cooperating genetic lesions for BCP-ALL to develop. Deletions affecting the transcriptional coregulator BTG1 are frequently observed in ETV6-RUNX1-positive leukemia. Here we report that Btg1 deficiency enhances the self-renewal capacity of ETV6-RUNX1-positive mouse fetal liver-derived hematopoietic progenitors (FL-HPCs). Combined expression of the fusion protein and a loss of BTG1 drive upregulation of the proto-oncogene Bcl6 and downregulation of BCL6 target genes, such as p19Arf and Tp53. Similarly, ectopic expression of BCL6 promotes the self-renewal and clonogenic replating capacity of FL-HPCs, by suppressing the expression of p19Arf and Tp53. Together these results identify BCL6 as a potential driver of ETV6-RUNX1-mediated leukemogenesis, which could involve loss of BTG1-dependent suppression of ETV6-RUNX1 function.

Originele taal-2Engels
Pagina's (van-tot)57-62.e3
TijdschriftExperimental hematology
StatusGepubliceerd - apr. 2018


Duik in de onderzoeksthema's van 'Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1'. Samen vormen ze een unieke vingerafdruk.

Citeer dit